Skip to main content
. 2015 Sep 3;6(31):30929–30938. doi: 10.18632/oncotarget.5131

Figure 2. Kaplan-Meier analysis of PFS according to baseline EGFR/MET Index in NSCLC patients (N = 27, all genotypes included) treated with EGFR TKIs.

Figure 2

A striking separation of PFS was observed between NSCLC patients with high EGFR/MET relative ratio vs. low EGFR/MET relative ratio at multiple cut-offs.